ClinicalTrials.gg
RecruitingNCT03839992Updated Oct 26, 2023

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

An observational study in Cystic Fibrosis in Children, sponsored by Gelb, Arthur F., M.D.. Recruiting at 2 sites in United States. Open to participants aged 5 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Gelb, Arthur F., M.D. · Observational

How we know

From the registry’s dates

  • Started Apr 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
5 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Planned enrollment
7th of 13
100 · median 100
Started
2018
with 3 others
Observational
13 of 65
6 open now
Primary completion
2027-04
later than 9 of 21 live
Registered
31st of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2018, is one of 13 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 31st registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 5 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

Goal is to physiologically detect unsuspected small airways obstruction in children and adults with treated heterozygous and homozygous cystic fibrosis. Unsuspected refers to normal routine pre bronchodilator spirometry including normal FEV1(L), FVC (L). and FEV1/FVC%. This is a retrospective study.

Read the detailed description

The current study is based on current investigators previously published patho-physiologic and lung CT studies in small airways intrinsic obstruction, emphysema, and asthma. Current investigators have demonstrated that despite the presence of normal routine spirometry including normal FEV1(L), FVC (L), and FEV1/FVC% that unsuspected small airways obstruction, and emphysema can be detected. This has been achieved by presence of isolated abnormal expiratory airflow limitation at low lung volumes on the maximal expiratory flow volume curves. This includes abnormal expiratory airflow at 75% and 80% expired lung volume. Current investigators believe investigators will be able to detect unsuspected small airways intrinsic obstruction, and peripheral airway bronchiectasis proven by lung CT, in patients with cystic fibrosis despite presence of pre bronchodilator normal routine spirometry.

03

Conditions studied

  • Cystic Fibrosis in Children

Browse trials for

Keywords

  • abnormal FEF75
  • bronchiectasis
  • lung CT
04

Who can participate

Ages eligible
5 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Review pulmonary function and radiologic studies in retrospective records of heterozygote or homozygote patients with cystic fibrosis

Eligibility criteria

Inclusion Criteria:

Heterozygote or homozygote patients with cystic fibrosis with normal routine pre bronchodilator spirometry including normal (L), FVC(L) and FEV1/FVC%.

Exclusion Criteria:Heterozygote or homozygote patients with cystic fibrosis with ABNORMAL routine pre bronchodilator spirometry

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testspirometry

    measure spirometry and lung CT

06

What researchers measure

Primary outcomes

  1. Detection of Unsuspected Small Airway Obstruction in Cystic Fibrosis

    Retrospective analysis of pre bronchodilator spirometry, and lung CT study to detect abnormal FEF75% in the presence of normal spirometry and FEF25-75. Detect isolated abnormal pre bronchodilator spirometry at 75%FVC

    Time frame: 5 years

07

Study locations

2 of 2 sites recruiting
  • Arthur F Gelb MD
    Lakewood, California 90712, United States
    Recruiting
    • Arthur F Gelb, MD · Contactafgelb@msn.com · 562-633-2204
    • Christine Fraser · Contactfamilyfrase@msn.com · 562-633-2204
    • Arthur F Gelb, MD · Principal investigator
  • Miller Children's Hospital and Long Beach Medical Center
    Long Beach, California 90806, United States
    Recruiting
08

References and documents

Publications

  • Mead J. The lung's "quiet zone". N Engl J Med. 1970 Jun 4;282(23):1318-9. doi: 10.1056/NEJM197006042822311. No abstract available. PubMed 5442364 ↗
  • Gelb AF, Gold WM, Wright RR, Bruch HR, Nadel JA. Physiologic diagnosis of subclinical emphysema. Am Rev Respir Dis. 1973 Jan;107(1):50-63. doi: 10.1164/arrd.1973.107.1.50. No abstract available. PubMed 4683321 ↗
  • Gelb AF, Zamel N. Simplified diagnosis of small-airway obstruction. N Engl J Med. 1973 Feb 22;288(8):395-8. doi: 10.1056/NEJM197302222880805. No abstract available. PubMed 4684043 ↗
  • Hogg JC, Pare PD, Hackett TL. The Contribution of Small Airway Obstruction to the Pathogenesis of Chronic Obstructive Pulmonary Disease. Physiol Rev. 2017 Apr;97(2):529-552. doi: 10.1152/physrev.00025.2015. Erratum In: Physiol Rev. 2018 Jul 1;98(3):1909. doi: 10.1152/physrev.00011.2018. PubMed 28151425 ↗
  • Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015 Sep;50(9):863-8. doi: 10.1002/ppul.23234. Epub 2015 Jun 16. PubMed 26079395 ↗

Individual participant data

Plan to share: Yes — All individual published data will be shared

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: when published

Access criteria: published data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2018 (actual). Primary completion is estimated for Apr 2027, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2019
First posted
Feb 15, 2019
StartActual
Apr 25, 2018
Primary completionEst.
Apr 25, 2027
CompletionEst.
Nov 25, 2027
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03839992
Lead sponsor
Gelb, Arthur F., M.D.
Collaborators
Miller Children's & Women's Hospital Long Beach, Stony Brook University, The Hospital for Sick Children
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Apr 25, 2018
Primary completion
Apr 25, 2027 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
Oct 26, 2023

Study contacts

Arthur F Gelb, MD
Contact
afgelb@msn.com
562-565-5333 ext. 5625655333
Vicki Masson, MD
Contact
vicki.masson@gmail.com
631-741-0549 ext. 5625655333
Arthur Gelb, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion